$-0.31 EPS Expected for Celsion Corporation (CLSN)

February 20, 2018 - By Hazel Jackson

 $ 0.31 EPS Expected for Celsion Corporation (CLSN)

Analysts expect Celsion Corporation (NASDAQ:CLSN) to report $-0.31 EPS on March, 15.They anticipate $1.65 EPS change or 84.18 % from last quarter’s $-1.96 EPS. After having $-0.39 EPS previously, Celsion Corporation’s analysts see -20.51 % EPS growth. The stock decreased 2.65% or $0.06 during the last trading session, reaching $2.2. About 216,946 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since February 20, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Celsion Corporation (NASDAQ:CLSN) Ratings Coverage

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Friday, August 7 with “Buy”. Maxim Group maintained Celsion Corporation (NASDAQ:CLSN) on Tuesday, January 19 with “Buy” rating. Zacks upgraded Celsion Corporation (NASDAQ:CLSN) rating on Wednesday, August 12. Zacks has “Hold” rating and $2.50 target. The rating was initiated by Oppenheimer on Monday, November 20 with “Buy”. The firm earned “Hold” rating on Thursday, November 10 by Maxim Group. The firm has “Buy” rating by Maxim Group given on Thursday, October 5. The stock of Celsion Corporation (NASDAQ:CLSN) has “Hold” rating given on Tuesday, August 15 by Maxim Group. On Thursday, June 1 the stock rating was maintained by Maxim Group with “Hold”. Maxim Group maintained the stock with “Hold” rating in Monday, August 7 report.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $39.02 million. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

More notable recent Celsion Corporation (NASDAQ:CLSN) news were published by: Investorplace.com which released: “FDA Win Sends Celsion Corporation (CLSN) Shares Higher” on January 04, 2018, also Globenewswire.com with their article: “Celsion Corporation to Delist from the Tel Aviv Stock Exchange” published on August 04, 2017, Globenewswire.com published: “Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides …” on November 14, 2017. More interesting news about Celsion Corporation (NASDAQ:CLSN) were released by: Seekingalpha.com and their article: “Celsion Turns Up The Heat On Cancer” published on November 23, 2017 as well as Globenewswire.com‘s news article titled: “Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, “TARDOX …” with publication date: November 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.